Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs, such as various solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Sagimet Biosciences Inc.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on RegenXBio (RGNX) and Sagimet Biosciences, Inc. Cla...

Analysts Offer Insights on Healthcare Companies: RegenXBio (RGNX) and Sagimet Biosciences, Inc. Class A (SGMT)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Immunic (IMUX), Legend Biotech (LEGN) and Sagimet Bi...

Analysts Offer Insights on Healthcare Companies: Immunic (IMUX), Legend Biotech (LEGN) and Sagimet Biosciences, Inc. Class A (SGMT)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Autolus Therapeutics (AUTL), Urogen Pharma (URGN) an...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Sagimet Biosciences, Inc. Class A ( ($SGMT) ) just unveiled an announcement. Sagimet Biosciences reported its second-quarter 2026 results on August...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SGMT	$10.94	+0.18%	1.25M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SGMT	$10.94	+0.2%	1.25M
3
4
5
6

SGMT

Get Sagimet Biosciences Inc. Data in Excel

Get Sagimet Biosciences Inc. Data in Excel